Therapeutic Potential of Endocannabinoid-Hydrolysing Enzyme Inhibitors
Action of Celecoxib on Hepatic Metabolic Changes Induced by the Walker-256 Tumour in Rats
Protective Effects of Sasanquasaponin on Injury of Endothelial Cells Induced by Anoxia and Reoxygenation in vitro
Combination Therapy of Rosiglitazone, a Peroxisome Proliferator-Activated Receptor-γ Ligand, and NMDA Receptor Antagonist (MK-801) on Experimental Embolic Stroke in Rats
Effect of Antipsychotics on Creatine Kinase Activity in Rat Brain
Effects of Marjoram Volatile Oil and Grape Seed Extract on Ethanol Toxicity in Male Rats
Comparison of Reactivating and Therapeutic Efficacy of Two Salts of the Oxime HI-6 against Tabun, Soman and Cyclosarin in Rats
Protection of Arsenic-Induced Hepatic Disorder by Arjunolic Acid
Pharmacokinetics of Two Randomized Trials Evaluating the Safety and Efficacy of Indinavir, Saquinavir and Lopinavir in Combination with Low-Dose Ritonavir : The MaxCmin1 and 2 Trials*
Ellagic Acid Prevents Cisplatin-Induced Oxidative Stress in Liver and Heart Tissue of Rats
The in vitro Inhibitory Potential of Trade Herbal Products on Human CYP2D6-Mediated Metabolism and the Influence of Ethanol
The endothelin receptor blocker bosentan inhibits doxorubicin-induced cardiomyopathy : I–1
Harmonization of the work of the ethics committees in Germany : I–2
Pharmacotherapy with current oral antidiabetic drugs : I–3
Influence of nanostructured calcium-phosphate particles on rat osteosarcoma cells : I–4
New pharmacological principles in the therapy of type 2 diabetes mellitus : I–5
Opportunities for joint pharmacovigilance activities : I–6
Vaccination against human pathogen papilloma viruses : I–7
Role of intestinal uptake transporters for the pharmacokinetics of drugs : I–8
Inclusion of women in clinical trials : I–9
New aspects of cytochrome P450 research : I–10
Non-responder to psychiatric drug treatment : I–11
Evaluation of pediatric studies by the ethics committee : I–12
Initial experience with ertapenem in clinical practice : treatment of fifty patients with chemotherapy-induced febrile neutropenia in an outpatient setting
Specific aspects and challenges of clinical trials in children : I–14
Mapping translational research in personalized therapeutics : from molecular markers to health policy
Randomized controlled trials as obligatory requirement of cost-effectiveness analysis? Study assessment by BfArM and IQWiG : I–16
European regulations for first-in-human clinical trials : I–17
Therapeutic improvement in lymphoblastic leukaemia therapy : I–18
Non-compliance : I–19
New drug delivery systems : I–20
Drug-eluting stents in coronary artery disease : I–21
Limited significance of randomized controlled trials : I–22
Cancer immunotherapeutics : from perspectives to reality of phase III development
Role of membrane transporters in liver disease : PMS–1
Hepatic porphyrias : pathogenesis and clinical outcomes
Hepatotoxicity in drug development : clinical control, early signals and pre-clinical prediction
Therapy of chronic viral hepatitis : an update
First administration of the novel selective dihydrofolate reductase inhibitor iclaprim in healthy male volunteers : C–1
Calcium balance during administration of calcium carbonate or sevelamer in individuals with normal renal function : C–2
Update on safety and antitumour effects of an oncolytic herpes simplex virus, NV1020, administered repeatedly via hepatic artery infusion prior to second-line chemotherapy, in patients with colorectal adenocarcinoma metastatic to the liver : C–3
Fentanyl produces higher vagal effects in comparison to sufentanil : C–4
Differential opioid action on sensory and affective cerebral pain processing assessed by functional magnetic resonance imaging : C–5
Aspirin and ibuprofen reduce nicotinic acid induced flushing : C–6
Voriconazole therapeutic drug monitoring : C–7
Correlation of near-infrared laser-induced tumour fluorescence intensities with the intratumoural structures quantified histologically by using stereological tools : C–8
Methylphenidate and sulpiride plasma concentrations as related to pharmacological functional magnetic resonance imaging in healthy male volunteers : C–9
Characterization of vascular reactivity after pioglitazone and candesartan treatment in healthy subjects : C–10
First results of a first-in-man proof of concept study of an anti-CD4mAb-fragment for the imaging of chronic inflammation in patients with active rheumatoid arthritis : C–11
Label versus off-label use for an antibiotic with clearly defined approval (indication) in Dresden, Saxony : C–12
The effects of venlafaxine on autonomic functions in healthy subjects : C–13
Haemodynamic changes induced by eating and long-lasting supine position in healthy men : C–14
Adjuvant vaccination after nephrectomy prolongs overall survival in patients with renal cell carcinoma : C–15
Hospital admissions due to adverse antibiotic reactions : C–16
Individualization of pharmacotherapy in old patients decreases the risk of adverse drug interactions occurrence : C–17
Optimization of pain pharmacotherapy in old patients : C–18
Effect of the dual pathway inhibitor cimetidine on the pharmacokinetics of roflumilast and its active N-oxide : K–1
Enterohepatic circulation of the THC-metabolite 11-nor-Δ9-carboxy-tetrahydrocannabinol (CTHC) after intravenous administration of CTHC in healthy human subjects : K–2
No effect of high-dose metronidazole on cytochrome P450 3A activity in a drug interaction study with the sensitive substrate budesonide : K–3
CYP3A4 phenotyping by plasma 4β-hydroxycholesterol? : K–4
Isolation and analytical assay development of 8-hydroxy-efavirenz for the quantification in plasma : K–5
Pharmacokinetics and metabolism of voriconazole in patients : K–6
Influence of ketoconazole on the pharmacokinetics and safety of intravenous iclaprim : K–7
Impact of long-term (14 days) efavirenz administration on CYP3A4 activity : K–8
Influence of concomitant administration of St. John's wort and ritonavir on CYP3A4 activity : K–9
Tissue penetration and pharmacokinetics of moxifloxacin at steady state in patients with diabetic foot infections : K–10
Posaconazole serum concentrations in patients before and after the day of stem cell transplantation : K–11
Disposition of sirolimus is not influenced by comedication of ezetimibe in healthy subjects : K–12
Metabolic disposition of flupirtin in man assessed by LC-MS and HRMS : K–13
Comparison of predicted and observed drug serum levels in pediatric patients using the physiology-based pharmacokinetic model PK-SIM® : a pilot study
Pharmacokinetic/Pharmacodynamic modelling as a tool to define safe dosing regimens for evaluation of dose response of tanogitran (BIBT 986), a novel small molecule parenteral anticoagulant, in a model of endotoxin-induced, tissue factor-triggered coagulation activation in human beings : K–15
Penetration kinetics of moxifloxacin after intravenous application in rat and human pancreas : K–16
The influence of oral antidiabetics on the uptake of organic cations mediated by organic cation transporter 1 : T–1
P-Glycoprotein expression in human sigmoidal and rectal biopsies in mesalazine-treated patients with ulcerative colitis : T–2
Induction of ATP-binding cassette transporters by efavirenz in vitro : T–3
Missense mutations in the multidrug resistance-associated protein 2 (MRP2/ABCC2) and 4 (MRP4/ABCC4) : impact on protein expression and drug tansport
Functional characterization of cell lines stably transfected with the organic anion transporting polypeptide 4A1 : T–5
Metabolism of tilidine by human liver microsomes, CYP3A4 and CYP2C19 : T–6
Bioavailability of voriconazole and its metabolites in human beings : T–7
The A270S polymorphism in the human kidney xenobiotic transporter OCT2 exhibits altered function : T–8
Altered ATP-binding cassette transporters in human heart failure : impact on channel conductivity and drug disposition
Bendamustine phase I metabolism in human beings : T–10
Role of CYP2E1 and GSTs in the toxicokinetics of acrylamide and its metabolites in human beings : T–11
Impact of CYP3A4, CYP3A5 and ABCB1 genotype and intestinal expression on the pharmacokinetics of budesonide : T–12
Measurement of telomerase activity and inhibition in non-small cell lung carcinoma by a modified telomeric repeat amplification protocol : G–1
Glutathione S-transferase P1, M1, T1 polymorphisms in patients with colorectal cancer : G–2
Multiplex analysis of vitamin D receptor and related metabolism gene polymorphisms : G–3
Impact of genetic variants on duodenal expression and on inducibility of ABCC2 and on disposition of talinolol : G–4
Impact of CYP2C9 and CYP2C19 polymorphisms on clinical efficacy of CHOP and R-CHOP therapy of follicular lymphoma : G–5
Results and indications that breast cancer patients could have a benefit from an anti-IL-6 treatment regiment : G–6
Effects of the HIV-1 protease inhibitor tipranavir on platelet aggregation in patients and in vitro and on in vitro thromboxane B2 formation : G–7
Glutathione S-transferase polymorphisms and clinical characteristics in patients with colorectal cancer : G–8
Differential expression of ppET-1 depending on a +138A insertion in the 5′-UTR of ET-1 gene : G–9
Impact of ABCA1 and MPO variants on plasma lipid levels of CAD patients : G–10
Influence of telmisartan on nitric oxide-asymmetric dimethylarginine system : role of AT1R and PPARγ signalling during the process of endothelial ageing
Determination of TPMT polymorphisms in different ethnic groups by MALDI-TOF MS : G–12
Genetic variation in nucleoside transporters hENT1 and hCNT1 in relation to transporter expression and cytotoxic effects of pyrimidine analogues : G–13
Non-synonymous polymorphisms in the human SLCO1B1 gene : an in vitro analysis of SNP 1929A>C
NOD2/CARD15 gene variants are linked to failure of antibiotic treatment in perianal fistulating Crohn's disease : G–15
Anti-rhinovirus-specific activity of the α-sympathomimetic oxymetazoline : G–16
OATP1B1 polymorphisms and torsemide pharmacokinetics and pharmacodynamics : G–17
The incidence of adverse events in first-in-man trials : O–1
Experiences from 5-year therapeutic drug monitoring of the human immunodeficiency virus drugs lopinavir, nelfinavir, saquinavir, fosamprenavir, efavirenz, nevirapine, lamivudine, abacavir and zidovudine : O–2
Drug information service for physicians : experiences from more than 10 years in Dresden
Are you familiar with your medication? Results of a knowledge test on Marcumar® : O–4
Therapeutic drug monitoring in psychiatry : clinical pharmacological comments and genotyping as pharmacovigilance tools
Six-year experiences with a drug information service for patients : O–6
Saliva-based CYP1A2 phenotyping integrated in a clinical pharmacology curriculum : O–7
An algorithm-based drug information tool for drug prescription during pregnancy : O–8
Timolol concentration in the human breast milk of a patient with glaucoma : O–9
Impact of computerized decision support for drug switching at the interface between primary and tertiary care : O–10
Substantial reduction of inappropriate tablet splitting with computerized decision support : O–11
Value of defined daily doses for the detection of overdoses in electronic prescriptions : O–12
Successful development of a comprehensive database model integrating data of clinical research and the current drug market for computerized decision support : O–13
Are pharma pipelines sustainable? A prediction of future pharma output : O–14
Changes of the prescription frequency of angiotensin-converting enzyme inhibitors in Saxony over a 2-year interval : O–15
Authorization of clinical trials : O–16
Clinical pharmacological ward rounds and therapeutic drug monitoring as parts of a drug and therapy information service to detect and prevent severe, rare adverse effects : two case reports
Systematic review : non-chemotherapy drug-induced agranulocytosis in children
Cytochrome P450 2D6, 2C9 and 2C19 polymorphisms and the risk of non-chenmotherapy drug-induced agranulocytosis : V-2
Suicide attempt of a young adolescent with attention-deficit hyperactivity disorder after change of the methylphenidate product : V-3
Drugs causing blood dyscrasias, hepatitis or pancreatitis : evidence from the pharmacovigilance center Berlin (PVZ — FAKOS)
Phenprocoumon-associated bleedings : influence of CYP2C9 and VKORC1
The use of inappropriate medications in the old does not substantially contribute to the occurrence of serious adverse drug reactions leading to hospital admission : V-6
Insulin-related hypoglycaemia : analysis of compliance, glycaemic control, kidney function and adverse drug reaction-related changes in the pharmacotherapy
Drug–drug interactions leading to hospital admission in the old : data from the German Pharmacovigilance Study Group
VKORC1-, CYP2C9- and CYP3A5-polymorphisms in patients with complicated phenprocoumon therapy : V-9
Frequency of serious adverse drug reactions associated with substrates of the polymorphic enzymes CYP2C9, CYP2C19 and CYP2D6 : V-10